sexual health

Sexual Health & Vitality Protocol

Central Arousal Activation, Hormonal Optimization & Desire Enhancement

strong evidence

A comprehensive peptide protocol targeting sexual function at the neurological level through melanocortin receptor activation and hypothalamic-pituitary-gonadal axis optimization. This evidence-based approach addresses low libido, arousal difficulties, and sexual dysfunction in both men and women.

intermediate

Difficulty

1-2 hours (acute)

First Results

As needed or 8-12 weeks

Duration

$150-400

Monthly Cost

Overview

Who This Protocol
Is Designed For

“Unlike medications that work peripherally on blood flow, PT-141 activates desire at its source—the brain's melanocortin receptors that govern arousal and sexual motivation. This FDA-approved approach addresses what happens before the bedroom, not just during.”

Ideal Candidates

Women with hypoactive sexual desire disorder (HSDD)—low desire causing distress
Men with erectile dysfunction not fully responsive to PDE5 inhibitors
Those experiencing low libido due to stress, aging, or hormonal changes
Individuals seeking to enhance sexual experience beyond baseline function
Couples wanting to address mismatched desire levels

Contraindications

Uncontrolled hypertension (PT-141 can temporarily raise blood pressure)
History of cardiovascular disease (consult cardiologist first)
Currently taking PDE5 inhibitors (sildenafil, tadalafil)—use with caution
Pregnancy or breastfeeding
History of severe nausea disorders

Expected Outcome

PT-141 typically produces noticeable effects within 45 minutes to 2 hours, lasting 6-12 hours. Users report increased desire, arousal, and sexual satisfaction. Phase 3 trials showed statistically significant improvements in desire and reduced distress in women with HSDD. Men report enhanced erections and libido.

The Science

Mechanism of Action
& Evidence Base

How It Works

Peptide

Mechanism

Biological Rationale

Targeted metabolic intervention at the receptor level

PT-141 (Bremelanotide) is a melanocortin receptor agonist that primarily activates MC4R and MC3R in the hypothalamus—brain regions governing sexual desire and arousal. Unlike PDE5 inhibitors that work peripherally on blood flow, PT-141 acts centrally to increase sexual motivation and desire. Kisspeptin modulates the HPG axis, stimulating GnRH release which increases LH and FSH, optimizing hormonal environment for sexual function.

Sexual desire originates in the brain's reward and motivation circuits, not the genitals. The melanocortin system is a key regulator of arousal, with MC4R activation directly linked to increased sexual behavior in both sexes. By targeting this central mechanism, peptides can address the psychological and neurological components of sexual dysfunction that peripheral treatments cannot reach.

Human Studies

100

Animal Studies

In Vitro Studies

strong

Evidence Strength

Key Findings

PT-141 (Bremelanotide) FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women
Phase 3 RECONNECT trials: statistically significant improvements in desire and reduced distress across all age, weight, and BMI subgroups
Kisspeptin administration substantially modulates sexual brain processing in men with HSDD, with increases in penile tumescence (JAMA Network Open, 2023)
PT-141 effective in men with ED non-responsive to sildenafil in clinical trials
Effects are central (brain-mediated), not dependent on peripheral blood flow mechanisms

Limitations

Maximum 8 doses per month recommended for PT-141 to prevent tachyphylaxis
Nausea is a common side effect, especially at higher doses
Blood pressure monitoring recommended in those with hypertension
Long-term use data beyond 52 weeks is limited

Protocol Tiers

Choose Your
Protocol Level

Best For

Those with occasional low desire, wanting enhancement for specific encounters, or exploring peptide effects for the first time

Cycle Duration

Ongoing as needed

Off-Cycle

None required if staying within monthly limits

PT-141 on-demand protocol for situational use—the FDA-approved approach for addressing low desire and enhancing sexual encounters as needed

Peptide

PT-141 (Bremelanotide)

Dose Range

1000-2000 mcg

Frequency

as-needed

Route

subcutaneous

Duration

As needed, ongoing

Timing

45-60 minutes before sexual activity for optimal effect

Special Instructions

Start with 1mg to assess tolerance. Nausea is common—diminishes with experience. Do not exceed 1.75mg per dose or 8 doses per month. Can be used by both men and women.

When to Stop

Severe nausea that doesn't improve
Significant blood pressure increase
Allergic reaction
Headache that persists beyond 24 hours

Peptide Database

Sexual Health & Vitality Protocol

Who This ProtocolIs Designed For

Ideal Candidates

Contraindications

Mechanism of Action& Evidence Base

Peptide

Key Findings

Limitations

Choose YourProtocol Level

PT-141 (Bremelanotide)

When to Stop

Who This Protocol
Is Designed For

Mechanism of Action
& Evidence Base

Choose Your
Protocol Level